Drug Trial Radar · NCT07841210
Fosrolapitant and Palonosetron for Highly Emetogenic ADC-Induced Nausea and Vomiting in Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Actual
Start
Sep 14, 2026
Primary completion
Jan 31, 2028
Study completion Jan 31, 2028
Sponsor
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Nanyang Central Hospital; Hubei Cancer Hospital
- First posted
- Sep 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the efficacy and safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in preventing nausea and vomiting induced by highly emetogenic antibody-drug conjugate (ADC) therapy in patients with solid tumors. A total of 60 patients are planned to be enrolled and divided into two groups: Group A will receive Fosrolapitant and Palonosetron Hydrochloride for Injection plus Dexamethasone plus Olanzapine, and Group B will receive Fosrolapitant and Palonosetron Hydrochloride for Injection plus Dexamethasone.
Conditions
- Solid Tumor Cancer
Interventions
Fosrolapitant and Palonosetron; Dexamethasone; OlanzapineDrug
HR20013 IV on D1; Dexamethasone 12 mg PO QD on D1, 3.75 mg PO BID on D2-4; Olanzapine 5 mg PO on D1-4
Fosrolapitant and Palonosetron; DexamethasoneDrug
HR20013 IV on D1; Dexamethasone 12 mg PO QD on D1, 3.75 mg PO BID on D2-4
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects achieving complete response (CR) during Days 0-21 after study drug administration in Cycle 1 (defined as no emetic episodes and no rescue medication use).Time frame: Day 0-21 after first treatment cycle 1 dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.